Periprosthetic joint infection (PJI) is one of the most
|
|
- Kerry Hoover
- 5 years ago
- Views:
Transcription
1 Bulletin of the Hospital for Joint Diseases 2014;72(4): Periprosthetic Joint Infection in Patients Receiving TNFα Antagonists Nimrod Snir, M.D., Ran Schwarzkopf, M.D., M.Sc., Michael Sobieraj, M.D., Ph.D., Andrew J. Lovy, M.D., M.Sc., and James D. Slover, M.D., M.Sc. Abstract Tumor necrosis factor-α antagonists (anti-tnfα) have become increasingly more common as a treatment for rheumatoid arthritis (RA). However, there has been an increased incidence of severe infections in patients taking anti-tnfα therapy. We present a case series of RA patients treated with anti-tnfα therapy that had previously underwent TJA and subsequently developed periprosthetic infections. All patients had a well-functioning implant for a period of 1 to14 years prior to the development of infection. Each patient underwent two to five different joint replacements, and four patients developed infection in multiple sites. The infections proved difficult to eradicate with four patients requiring multiple procedures, and one patient ultimately requiring a hemipelvectomy. This study suggests that periprosthetic infections acquired by patients on anti-tnfα therapy are challenging to eradicate and treat; highlighting the need for the establishment of guidelines for perioperative and long-term management of anti-tnfα therapy, and infection monitoring in joint replacement patients. Nimrod Snir, M.D., Michael Sobieraj, M.D., Ph.D., Andrew J. Lovy, M.D., M.Sc., and James D. Slover, M.D., M.Sc., Department of Orthopaedic Surgery, NYU Hospital for Joint Diseases, Langone Medical Center, New York, New York. Ran Schwarzkopf, M.D., M.Sc., Department of Orthopaedic Surgery, University of California, Irvine, Orange, California. *The two first authors contributed equally to the preparation of the manuscript. Correspondence: Ran Schwarzkopf, M.D., M.Sc., Department of Orthopaedic Surgery, University of California, Irvine, 101 The City Drive South, Orange, California 92868; schwarzk@gmail.com. Periprosthetic joint infection (PJI) is one of the most significant and costly problem facing adult reconstruction surgeons. A recent review of total hip arthroplasties (THA) performed in the Medicare population showed an incidence of PJI of 1.63% within 2 years of surgery and of 0.59% between 2 and 10 years postoperatively. 1 A similar review of total knee arthroplasties (TKA) found that within 2 years of surgery the incidence of PJI was 1.55%, and at 2 to 10 years postoperatively the incidence was 0.46%. 2 An analysis of the economics of PJI 3 showed that the average total costs in 2009 for a revision of an infected hip was $93,600 and $74,900 for a knee. The total cost to the health care system of PJI in 2009 was $566 million and is projected to reach $1.62 billion by Since their introduction in the late 1990s, biologic agents, such as tumor necrosis factor-α (TNFα) antagonists, have been an increasingly used modality for treating RA, especially RA that is recalcitrant to management with conventional disease modifying anti-rheumatic drugs (DMARDs). Multiple randomized controlled trials have confirmed the efficacy of TNFα antagonists in RA, demonstrating reduced disease activity and radiographic progression, with multiple meta-analyses confirming these findings. 4-6 This gives hope that the need for multiple TJAs in RA patients will be somewhat muted by these newer agents. 7 However, there has been concern with the potential for increased malignancy and infection in patients with anti TNFα therapy A review of the literature finds that there is evidence of increased occurrence of serious infections (usually defined as needing a prolonged antibiotic course or hospitalization) in patients undergoing anti TNFα therapy. 8,11-14 This is in contrast to evidence that there is no increased risk of serious infections for certain DMARD agents. 15 One study comparing patients before and after initiation of TNFα therapy found that the rate of serious infections in these patients more than doubled after initiation Snir N, Schwarzkopf R, Sobieraj M, Lovy AJ, Slover JD. Periprosthetic joint infection in patients receiving TNFα antagonists. Bull Hosp Jt Dis. 2014;72(4):253-8.
2 254 Bulletin of the Hospital for Joint Diseases 2014;72(4):253-8 of TNFα therapy, and that the only significant predictor (in a multivariate analysis) for developing an infection was a prior joint procedure (arthroplasty or arthrodesis). 14 Furthermore, there is limited evidence discussing the infection risk for patients, treated with anti TNFα therapy, after orthopaedic procedures, with no studies examining the change in risk for late onset PJI for patients started on TNFα DMARDs. We present a retrospective chart-review case series of nine RA patients treated with TNFα antagonists after previous TJA that went on to develop periprosthetic infections, followed by a review of the current literature on TNFα antagonists, infection, and TJA. Methods and Materials Study Design and Selection Criteria This retrospective case series was performed after IRB approval. Using the NYU Hospital for Joint Diseases Arthroplasty Registry, a retrospective review was conducted of nine consecutive patients who presented to our tertiary care medical center. All patients with previous hip or knee arthroplasty and who had a history of periprosthetic joint infections combined with a history of TNFα treatment were included in this case series. During this 9-year period, nine cases of late PJI after the start of TNFα treatment were found. Eight patients were treated with etanercept (Enbrel, Amgen, Thousand Oaks, CA, USA) and one patient with infliximab (Remicade, Janssen Biotech, Titusville, NJ, USA). Data Collection Information regarding RA disease course, RA medications, previous total joint arthroplasty, previous periprosthetic joint infections, and microbiological data were collected. Demographic and patient data were collected for all cases. Results We have found nine patients that met our inclusion criteria of late PJI after starting TNFα treatment. Patients had an average of 6.3 years (range: 1.5 to 14 years) of successful implantation prior to diagnosis of infection, with only one patient developing infection less than 2 years following arthroplasty. All of the patients had an average of three TJAs (range: two to five TJAs) at the time of being diagnosed with infection, and four of the nine patients had infection in multiple joints. All infections were considered hematogenous in etiology due to the symptom free period prior to presentation. The immunosuppressive treatment that the patients were receiving hindered our ability to establish an exact date of infection seeding. Among the nine patients, average age at infection was 54 (range: 36 to 65 years), average body mass index was 26.2 kg/m 2 (range: 19.5 to 34.7), and eight were female (Table 1). All patients had been diagnosed with RA at a mean of 22.2 years (range: 5 to 36 years), prior to their primary joint replacement surgery. Eight patients had been treated with etanercept, and one patient was treated with infliximab (Table 1). Among the 9 patients, there were 17 (8 knees, 6 hips, 2 ankles, and 1 shoulder) prosthetic joint infections, as several patients presented with polyarticular PJI. At presentation, patients had an average white blood cell count of 8.4 x 10 9 /L (range: 6.2 to 10.5 x 10 9 /L), erythrocyte sedimentation rate of 82.9 mm/hr (range: 30 to 120 mm/hr), and a C-reactive protein level of 93.4 mg/l (range: 12 to 158 mg/l). The most common identified bacterial organism was methicillin resistant Staphylococcus aureus, which was found in four patients, Streptococcus viridians in two patients, and methicillin sensitive Staphylococcus aureus in one patient. Two patients had polymicrobial infections with Enterobacter cloacae, Morganella morganii, Enterococcus, and alphahemolytic Streptococcus (Table 1). TNFα treatment was stopped when PJI was diagnosed and held during the entire treatment course for all patients. Two patients (three joints) were treated successfully with irrigation and debridement alone, three patients (five joints) were treated successfully with a two-stage revision, and two Table 1 Patient Demographics and Periprosthetic Joint Infection Data Patient No. Sex (M/F) R.A Medication Time to infection (years) Total Number of TJA Number of PJI (N = 17) Microorganism 1 M Etanercept MRSA 2 F Etanercept Streptococcus viridans 3 F Etanercept Multiple Organisms 4 F Etanercept Multiple Organisms 5 F Etanercept MRSA 6 F Infliximab MSSA 7 F Etanercept Multiple Organisms 8 F Etanercept MRSA 9 F Etanercept MRSA Average PJI = periprosthetic joint infection, RA = rheumatoid arthritis, MRSA = methicillin resistant Staphylococcus aureus, MSSA = methicillin sensitive Staphylococcus aureus.
3 Bulletin of the Hospital for Joint Diseases 2014;72(4): patients (two joints) had a successful two-stage revision after a failed irrigation and debridement. Some patients have proven to be more refractory to conventional twostage revisions: one patient failed two two-stage revisions and required a resection arthroplasty, two patients failed a two-stage revision and multiple irrigation and debridement attempts, which required a resection arthroplasty for one and hip disarticulation for the other, and one patient continued to have chronic infection, which needed suppressive antibiotic treatment. Discussion TNFα therapy in patients undergoing TJA and in patients with previous joint replacement can have serious consequences. A recent study 16 has shown that patients with multiple lower limb TJAs that get infected in a single joint have a 20% chance of becoming infected in another of their prosthetic joints, with an average time to second infection of 2 years. An older study 17 of patients with PJIs and multiple TJAs found a 19% incidence of additional PJI. This study also found that rheumatoid arthritis (RA) patients had more total joint arthroplasties (TJAs) on average than osteoarthritis (OA) patients, and that RA was highly associated with development of a second PJI, making this population particularly at risk. In one study spanning from 1974 to 1997, it was estimated that 25% of RA patients underwent one TJA within 22 years of disease onset, and of those, 50% had an additional TJA within 7 years. 18 In addition to being more susceptible to a second PJI, RA patients have an increased occurrence of initial PJI compared to the patients with OA, with studies identifying RA as an independent risk factor for this complication. 19 A recent study using data from the Norwegian Arthroplasty Registry, 20 of 108,786 THAs and TKAs performed on 6,629 patients with RA and 102,157 patients with OA, found that for THA, there is no increase in revision surgery for PJI in the first 6 years of implantation for RA compared with OA patients, but that after 6 years, there is a relative risk of 4.1 for revision surgery among the RA patients. For TKA, there was an initial increase in risk of PJI for the first postoperative year, which was not present for the next 5 years. The relative risk of revision for TKA for patients with RA was 5.4 after 6 years when compared with OA patients. This highlights the potential for late onset presentation of infection in patients with RA. Furthermore, no recommendation exists on proper follow up protocol for patients who start TNFα therapy and have had a joint replacement. The most relevant publication to our patient experience is a case report by Yurube and coworkers. 21 They present the case of a 54-year-old woman with RA. Infliximab therapy was started 3 years and 8 months after having undergone bilateral TKA. One week after the third administration of infliximab, the patient suffered sudden left knee pain and infectious clinical symptoms. The knee joint was found to be infected by MSSA. Plain radiographic film of the knee also showed multiple lytic lesions around the tibial component that had not been present prior to the onset of treatment. The investigators postulated that the patient might have been suffering from a chronic subclinical infection for a long time, and that the administration of anti-tnfα therapy allowed this to exacerbate into a serious infection. Much more has been written about the use of these agents in the perioperative period. However, despite this, currently, there is no consensus in the literature on the length of the suspension period of the medication prior to surgery. Some patients undergo TJA without suspending TNFα treatment at all. Previous studies have not clearly demonstrated risk with immune modulators and orthopaedic surgery. Recently the American College of Rheumatology released recommendations for the use of biologics in the perioperative period. 22 The consensus was that biologic DMARDs should be suspended for at least 1 week prior to and after surgery. However, according to the report, this should be adjusted according to the agent being used and according to infection risk with no guidelines given as to how this should be done. The 2013 International Consensus Group on Periprosthetic Joint Infection proposed a guideline based on medication half-life (Table 2). Talwalkar and colleagues 23 presented a case series of 11 patients (10 RA, 1 PA) that underwent 16 orthopaedic op- Table 2 Biologic Response Modifiers Treatment Recommendations Prior to Total Joint Replacement Surgery Biological Response Modifiers Half Life of Drug* Recommendation Etanercept 4.3 days Hold for at least 1.5 weeks prior and after Infliximab 8-10 days Hold for 3 weeks prior and after Golimumab days Hold for 1 month prior and after Tocilizumab days Hold for 1 month prior and after Abatacept days Hold for 1 month prior and after Adalimumab days Hold for 1 month prior and after Certolizumab days Hold for 1 month prior and after Rituximab 21 days Hold for 2 months prior and after *Recommendations adapted from the 2013 Periprosthetic Joint Infection International Consensus Meeting. 30
4 256 Bulletin of the Hospital for Joint Diseases 2014;72(4):253-8 erations ranging from hand operations to TJA. All patients were receiving etanercept, adalimumab, or infliximab. The operations were subdivided into 2 groups. Group A included four patients where there was no interruption in anti-tnfα therapy, and Group B included 12 patients in which therapy was halted for 2 weeks (adalimumab and etanercept) or 4 weeks (infliximab) prior to the procedure. The investigators found no difference in infection rates between the two groups in this small case study. Gilson and associates 24 published a case control study using cases from the French Ratio (Research Axed on Tolerance of Biotherapies) registry and a retrospective control group from a tertiary care center. Twenty patients who underwent TJA (12 knee, 5 hip, 2 shoulder, and 1 ankle) who were on anti-tnfα therapy and suffered infection were matched with 40 controls (each case was matched with 2 controls) that were on anti-tnfα therapy with a TJA and did not develop infection. The investigators analyzed risk factors for inquiring an infection. It was found that increased steroid intake, primary TJA within the last year, and revision of an infected prosthesis within the last year were all risk factors for a PJI. The investigators also showed a trend that if anti-tnfα therapy was not interrupted for 5 drug half-lives prior to surgery, there was an increased rate of infection. However, this trend did not reach statistical significance. A study by Bongartz and coworkers 25 included all patients with RA who underwent THA and TKA at the Mayo Clinic during a period of 8.5 years. This included 462 patients with 657 total hip and knee arthroplasties. A matched control cohort with osteoarthritis (OA) was also assembled. At 5-year follow up, this study showed that the infection rate for patients with RA was 4.2%, and for those with OA, it was 1.4%. In examining the patients that were on anti-biologic therapy at the time of TJA, they found that there were 3 infections in the 38 patients that did not suspend anti-tnfα therapy prior to surgery and none in the 12 patients that did suspend the treatment. However, this difference was not found to be statistically significant. Hayata and colleagues 26 studied 52 patients on infliximab therapy that had undergone orthopaedic surgery (including not only arthroplasty surgery but also spine surgery, arthroscopic synovectomy, ankle arthrodesis, hand surgery, and fracture care). For the subset of arthroplasty patients, there were five THA in three patients, seven TKA in six patients, two TSA in two patients, two TEA in two patients, and two toe arthroplasties in two patients. At 1 year, the investigators reported only 2 superficial infections in the entire 52 patients (1 toe arthroplasty, 1 spine surgery) with no deep infections. The investigators concluded that there was no significant effect of time between last infusion of infliximab and surgery. However, it should be noted that the mean time between last infusion and surgery was 4 weeks, and no range data was provided in the paper. Ruyssen-Witrand and associates 27 published a retrospective case study of 92 patients with RA receiving infliximab, etanercept, or adalimumab. The cohort underwent 127 surgical procedures. Patients were divided into five groups based on the risk of infection: three orthopaedic groups including low risk (such as arthrodesis, synovectomy, tendon surgery), moderate risk (such as primary TJA, and spinal fusion), and high risk (such as TJA revision); septic orthopaedic surgery; and all emergency surgery. The study examined the issue of interruption of TNFα DMARD therapy and found no statistically significant difference in total complication rate (infectious and non-infectious) between the patients whose therapy was interrupted for 5 drug half-lives versus those whose therapy was not interrupted or interrupted for a shorter amount of time prior to surgery. This non-significance continued when the threshold for withholding was lowered to 2 drug half-lives, although a trend appeared toward an increased complication rate in the non-interrupted group. However, the investigators did state that the orthopaedic complication rate for patients on anti-tnfα therapy (12% overall, 5.6% infectious) was higher than the rates reported in the literature for patients on conventional DMARDs. Kawakami and coworkers 28 conducted a retrospective pair matched case control study of 64 patients on anti-tnfα therapy and 64 matched controls on exclusively non-biologic DMARDs. Anti-TNFα therapy was withheld for 2 or 4 weeks prior to surgery for etanercept and infliximab, respectively. There were two branches of the study, one examining infection and one examining risk of DVT. Infection was defined using the CDC definition for surgical site infection: superficial infection within 30 days of surgery or deep infection within 30 days or within 1 year if an implant was left behind and the infection appears related to the implant. For the infection arm, the procedures included were TSA, TEA, MCP arthroplasty, wrist arthroplasty, TAA, THA, and TKA. The TNFα group experienced seven superficial surgical site infections and one deep infection requiring ROH. The non-biologic DMARD group only suffered one superficial infection. Multivariate analysis showed that disease duration, prednisone dosage, and anti-tnfα therapy were all risk factors for surgical site infection. Additionally, in the DVT wing of the study (which used a slightly different group of patients) it was shown that anti-tnfα therapy increased risk of DVT. Momohara and colleagues 29 performed a retrospective single center review of 420 TJAs in RA patients. There were 81 THAs with 11 of those performed on patients on biologic DMARDs and 339 TKAs with 37 being performed on patients on biologic DMARDs. Patients taking biologic DMARDs included three anti-tnfα drugs, such as infliximab, etanercept, and adalimumab, and one anti-il-6, such as tocilizumab. Of the 420 procedures, there were 24 superficial infections and three PJIs that required removal of hardware. Multiple logistic regression was used and found that both biologic DMARD use and duration of RA were significant risk factors of infection. The odds ratio for biologic DMARD use and sustaining a surgical site infection
5 Bulletin of the Hospital for Joint Diseases 2014;72(4): compared with conventional DMARDs was Given the difficulty and the severity of our cases presented in this case series, with one requiring a hemipelvectomy, it is important to appreciate the increased risk and clinical outcome of late infection among this patient group. Another difficulty in treating this patient group is accurately identifying the onset of the PJI and correctly differentiating between acute and chronic hematogenous PJI. Furthermore, if such patients incur a PJI, the outcomes of treatment of the PJI seem to be inferior to results of PJI treatment in patients that are not treated with anti-tnfα therapy. When consulting the patient, it is important to discuss the high chance of failure of irrigation and debridement alone, and the possibility of needing multiple procedures in order to eradicate the infection and achieve a good outcome. TNFα antagonists are powerful agents that can result in significant clinical improvement for some RA patients. However, this does come with increased risk for patients with previous total joint replacements of late infection, and further research is needed to quantify this risk so that appropriate protocols can be developed and so patients with total joint replacements can be appropriately counseled before initiating treatment with these agents. Disclosure Statement None of the authors have a financial or proprietary interest in the subject matter or materials discussed, including, but not limited to, employment, consultancies, stock ownership, honoraria, and paid expert testimony. References 1. Ong KL, Kurtz SM, Lau E, et al. Prosthetic joint infection risk after total hip arthroplasty in the Medicare population. J Arthroplasty Sep;24(6 Suppl): Kurtz SM, Ong KL, Lau E, et al. Prosthetic joint infection risk after TKA in the Medicare population. Clin Orthop Relat Res Jan;468(1): Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty Sep;27(8 Suppl):61-5.e1. 4. Aaltonen KJ, Virkki LM, Malmivaara A, et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord Apr 17;9: Blumenauer B, Judd M, Cranney A, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2003;4:CD da Silva E, Doran MF, Crowson CS, et al. Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum Apr 15;49(2): Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA May 17;295(19): Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis Jul;68(7): Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA sep 5;308(9): Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum Apr;56(4): Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum Dec;56(12): Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum Jun;56(6): Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) Feb;46(2): Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebocontrolled trials. Ann Rheum Dis Jan;68(1): Jafari SM, Casper DS, Restrepo C, et al. Periprosthetic joint infection: are patients with multiple prosthetic joints at risk? J Arthroplasty Jun;27(6): Luessenhop CP, Higgins LD, Brause BD, Ranawat CS. Multiple prosthetic infections after total joint arthroplasty. Risk factor analysis. J Arthroplasty Oct;11(7): Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum Jun;41(6): Pulido L, Ghanem E, Joshi A, et al. Periprosthetic joint infection: the incidence, timing, and predisposing factors. Clin Orthop Relat Res Jul;466(7): Schrama JC, Espehaug B, Hallan G, et al. Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108,786 hip and knee joint arthroplasties from the Norwegian Arthroplasty Register. Arthritis Care Res (Hoboken) Apr;62(4): Yurube T, Takahi K, Owaki H, et al. Late infection of total knee arthroplasty inflamed by anti-tnfalpha, infliximab therapy in rheumatoid arthritis. Rheumatol Int Jan;30(3): Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum Jun 15;59(6): Talwalkar SC, Grennan DM, Gray J, et al. Tumour necrosis
6 258 Bulletin of the Hospital for Joint Diseases 2014;72(4):253-8 factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis Apr;64(4): Gilson M, Gossec L, Mariette X, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor alpha-blockers: a case-control study. Arthritis Res Ther. 2010;12(4):R Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum Dec 15;59(12): Hayata K, Kanbe K, Chiba J, et al. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis Feb;14(1): Ruyssen-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol May-Jun;25(3): Kawakami K, Ikari K, Kawamura K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) Feb;49(2): Momohara S, Kawakami K, Iwamoto T, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol Oct;21(5): Musculoskeletal Infection Society. International Consensus on Periprosthetic Joint Infection. Available at: org/international-consensus.
Risk Factors for Infection Following Total Joint Arthroplasty in Rheumatoid Arthritis
Send Orders for Reprints to reprints@benthamscience.net The Open Rheumatology Journal, 2013, 7, 119-124 119 Open Access Risk Factors for Infection Following Total Joint Arthroplasty in Rheumatoid Arthritis
More informationPerioperative Medicine:
Perioperative Medicine: Management of rheumatologic agents Divya Gollapudi, MD May 2016 Medical Operative Consult Clinic Harborview Medical Center Your patient Ms. L is a 55 year-old F w/ h/o RA who presents
More informationPeriprosthetic joint infection: are patients with multiple prosthetic joints at risk?
Thomas Jefferson University Jefferson Digital Commons Rothman Institute Rothman Institute 6-1-2012 Periprosthetic joint infection: are patients with multiple prosthetic joints at risk? S Mehdi Jafari The
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationCankaya Ortopedi. Outpatient TKA in Rheumatoid Arthritis. Prof. N. Reha Tandogan, M.D
IMUKA 2016 Transatlantic Current Concepts in Outpatient Arthroplasty Dr. N. Reha Tandoğan Outpatient TKA in Rheumatoid Arthritis Prof. N. Reha Tandogan, M.D Ortoklinik / Çankaya Orthopaedics, Ankara, Turkey
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationHealthcare-associated infection: what the impact is and where the burden falls
Healthcare-associated infection: what the impact is and where the burden falls E. Tacconelli Dept. Infectious Diseases Catholic University, Rome, Italy Road map Incidence Mortality Lenght of hospitalisation
More informationPharmacy Medical Necessity Guidelines: Orencia (abatacept)
Pharmacy Medical Necessity Guidelines: Effective: October 23, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or
More informationThe Orthopaedic In-Training Examination (OITE)
168 Reconstructive Knee Surgery Literature as a Tool for the Orthopaedic In-Training Examination Siraj A. Sayeed, M.D., M. Eng., David R. Marker, B.S., Simon C. Mears, M.D., Ronald E. Delanois, M.D., and
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationAdherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA)
Adherence to Non-Infused Biologic Medications Used to Treat Rheumatoid Arthritis (PDC-RA) Description The percentage of patients 18 years and older with rheumatoid arthritis (RA) who met the Proportion
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationUpdate on Prosthetic Joint Infections 2017
Update on Prosthetic Joint Infections 2017 George F. Chimento, MD, FACS Chair, Department of Orthopaedic Surgery Associate Professor, University of Queensland School of Medicine Ochsner Medical Center
More informationPharmacy Medical Necessity Guidelines: Actemra (tocilizumab)
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or Medical
More informationPharmacy Medical Necessity Guidelines:
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More informationPharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab)
Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab) Effective: November 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical
More informationClassic DMARD s, biologic drugs and cancer risk
Classic DMARD s, biologic drugs and cancer risk Prof. Dr. António M. F. Araújo Head of the Service of Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas de Abel Salazar Disclosure
More informationThe Pennsylvania State University. The Graduate School. College of Medicine. The Department of Public Health Sciences
The Pennsylvania State University The Graduate School College of Medicine The Department of Public Health Sciences EVALUATION OF TWO PROCEDURES FOR TREATMENT OF KNEE PROSTHETIC JOINT INFECTION (PJI) A
More informationModifiable Risk Factors in Orthopaedic Infections
Modifiable Risk Factors in Orthopaedic Infections AAOS Patient Safety Committee Burden US Surgical Site Infections (SSI) by the Numbers ~300,000 SSIs/yr (17% of all HAI; second to UTI) 2%-5% of patients
More informationHip and Knee Osteoarthritis in Patients with Non-Insulin Dependent Diabetes Mellitus
Hip and Knee Osteoarthritis in Patients with Non-Insulin Dependent Diabetes Mellitus Laurie L. Jansky, MS, Zbigniew Gugala, MD, PhD. The University of Texas Medical Branch, Galveston, TX, USA. Disclosures:
More informationAbatacept: first T cell co-stimulation modulator for severe active RA
Abatacept: first T cell co-stimulation modulator for severe active RA Steve Chaplin MSc, MRPharmS and Andrew Ostor FRACP PRODUCT PROFILE Proprietary name: Orencia Constituents: abatacept Dosage and method
More informationPowered by Editorial Manager and ProduXion Manager from Aries Systems Corporation
Powered by Editorial Manager and ProduXion Manager from Aries Systems Corporation Powered by Editorial Manager and ProduXion Manager from Aries Systems Corporation 1 Original article 2 Risk factors for
More informationHip Arthroplasty Performance Measurement Set
American Association of Hip and Knee Surgeons Hip Arthroplasty Performance Measurement Set For Public Comment DRAFT January 4, 2016 Table of Contents Work Group Members 4 Executive Summary 5 Purpose of
More informationOrencia (abatacept) DRUG.00040
Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28
More informationC. Assess clinical response after the first three months of treatment.
Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationKey words: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, treatment access
6, 21...,.,..,..,. - (RA) -,. (AS) (PsA). (Disease-modifying antirheumatic drugs, DMARDs). DMARDs 21. - RA, AS PsA. 21. RA, DMARDs. Leflunomide (Arava)., RA Methotrexate Leflunomid. DMARDs - 5 29. - RA
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK)
The Hospital for Sick Children Technology Assessment at SickKids (TASK) THE USE OF BIOLOGIC RESPONSE MODIFIERS IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS Report No. 2010-01 Date: January 11,
More informationAnnual European Congress of Rheumatology (EULAR) Madrid, Spain, June 2017
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW DATA SUGGEST NO INCREASED CANCER RISK FOR RA PATIENTS PRESCRIBED BIOLOGICAL DMARDS Reassuring findings may positively
More informationInfection Risk After Orthopedic Surgery in Patients With Inflammatory Rheumatic Diseases Treated With Immunosuppressive Drugs
Arthritis Care & Research Vol. 65, No. 12, December 2013, pp 2032 2040 DOI 10.1002/acr.22077 2013, American College of Rheumatology ORIGINAL ARTICLE Infection Risk After Orthopedic Surgery in Patients
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationBy: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author s Line Manager:
For Use in: By: For: Guidelines for the Management of Interruption of Biologic Therapies for Division responsible for document: Key words: Name and job title of document author: Name and job title of document
More informationComplication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers A. Ruyssen-Witrand, L. Gossec, C. Salliot, M. Luc, M. Duclos, S. Guignard, M.
More informationThe GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015
The GPs role with biologics for immune-mediated inflammatory diseases David Gardner Rheumatologist GPCME 2015 The views and opinions expressed in the following presentation are those of the presenter and
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationSerum C-reactive protein levels correlate with clinical response in patients treated with antibiotics for wound infections after spinal surgery
The Spine Journal 6 (2006) 311 315 Serum C-reactive protein levels correlate with clinical response in patients treated with antibiotics for wound infections after spinal surgery Mustafa H. Khan, MD a,
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),
More informationMalnutrition: An independent Risk Factor for Postoperative Complications
Malnutrition: An independent Risk Factor for Postoperative Complications Bryan P. Hooks, D.O. University of Pittsburgh-Horizon June 24, 2017 Orthopedic Surgeon-Adult Reconstruction Disclosures: None Objectives:
More informationSkin cancers in patients treated with immunomodulating drugs. Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France
Skin cancers in patients treated with immunomodulating drugs Manuelle Viguier, MD, PhD Dermatology department Saint-Louis Hospital Paris, France Immunomodulating drugs used in Methotrexate Mycophenolate
More informationAn Analysis of Medicare Payment Policy for Total Joint Arthroplasty
The Journal of Arthroplasty Vol. 23 No. 6 Suppl. 1 2008 An Analysis of Medicare Payment Policy for Total Joint Arthroplasty Kevin J. Bozic, MD, MBA,*y Harry E. Rubash, MD,z Thomas P. Sculco, MD, and Daniel
More informationPharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol)
Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol) Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationPreliminary Report Choosing Wisely Identifying Musculoskeletal Interventions with Limited Levels of Efficacy in the Shoulder & Elbow.
Preliminary Report Choosing Wisely Identifying Musculoskeletal Interventions with Limited Levels of Efficacy in the Shoulder & Elbow. Prepared for The Canadian Orthopaedic Association Contents Executive
More informationSébastien LUSTIG MD, PhD, Prof *,** Tristan Ferry ** Frederic Laurent ** *Albert Trillat Center- Lyon, **CRIOA Lyon
SICOT Meeting Roma September 2016 Risk factors of periprosthetic infection and my experience of how to prevent an infection Sébastien LUSTIG MD, PhD, Prof *,** Tristan Ferry ** Frederic Laurent ** *Albert
More informationRheumatoid Arthritis Update
Rheumatoid Arthritis Update Beth Valashinas, DO, FACOI, FACR Disclosures Speaker for AbbVie Pharmaceuticals Learning Objectives Upon completion of this session, participants should be able to discuss:
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationElb-2: Does previous surgery (arthroscopic, fracture fixation, other nonarthroplasty) increase the risk of subsequent elbow PJI?
Elbow ICM 2018 Elb-2: Does previous surgery (arthroscopic, fracture fixation, other nonarthroplasty) increase the risk of subsequent elbow PJI? RESEARCHED BY: Barco Laakso, Raul MD, Spain Antuña, Samuel
More informationSummary of Risk Minimization Measures
Table 6.1.4-1: Summary of Risk Minimization Measures Safety Concern Vaccination Hepatic and renal impairment Combination therapy Elderly Routine Risk Minimization Measures Specific subsection on vaccination
More information6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline
Summary of Published Switch data Table 1. Information Patients Switch from (n) Reason for switch Switch to: (n) Results Numbers Presse Med. 2002 (1) 14 Infliximab (8) (6) 6 ADRs, 2 LOE 2 ADRs, 4 LOE (8)
More informationH.P. Teng, Y.J. Chou, L.C. Lin, and C.Y. Wong Under general or spinal anesthesia, the knee was flexed gently. In the cases of limited ROM, gentle and
THE BENEFIT OF ARTHROSCOPY FOR SYMPTOMATIC TOTAL KNEE ARTHROPLASTY Hsiu-Peng Teng, Yi-Jiun Chou, Li-Chun Lin, and Chi-Yin Wong Department of Orthopedic Surgery, Kaohsiung Veterans General Hospital, Kaohsiung,
More informationAmjevita (adalimumab-atto)
*- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Actemra) Reference Number: HIM.PA.SP32 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at
More informationDoes the SF-36 Mental Health Composite Score Predict Functional Outcome after Surgery in Patients with End Stage Ankle Arthritis?
Does the SF-36 Mental Health Composite Score Predict Functional Outcome after Surgery in Patients with End Stage Ankle Arthritis? Kennedy SA, Barske H, Penner M, Daniels T, Glazebrook M, Wing K, Dryden
More informationMarcin Borowski, Przemysław Bereza, Damian Kusz, Katedra i Klinika Ortopedii i Traumatologii Narządu Ruchu Śląski Uniwersytet Medyczny w Katowicach
Spacer as a source of re-infection? Comparison of cultures and 16s r-rna sequencing for identification for bacteria in 2-stage revision knee arthroplasty Marcin Borowski, Przemysław Bereza, Damian Kusz,
More informationDemand Regarding Enbrel (Etanercept)
July 1, 2009 Mr. Yoichi Masuzoe, Minister of Health, Labour, and Welfare Mr. Kazuhiko Mori, Director, Safety Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Mr.
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationHip Arthroscopy in Patients with Mild to Moderate Dysplasia: When do they Fail?
Hip Arthroscopy in Patients with Mild to Moderate Dysplasia: When do they Fail? Andrew J. Bryan 1, MD K. Poehling-Monaghan 1, MD Rohith Mohan 1, BA Nick R Johnson 1, BS Aaron J. Krych 1, MD Bruce A. Levy
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationPHARMACY POLICY STATEMENT Ohio Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Ohio Medicaid Enbrel (etanercept) Must use
More informationPeriprosthetic Infection
Periprosthetic Infection Donald W Hohman MD Greater Dallas Orthopaedics Dallas, TX Presented by Jay Pond, M.D. Common Scenarios Acute Infection (Less than 2 weeks of symptoms) Well Fixed Components 2 Stage
More informationMultiple joint reconstructions in one patient: computer-assisted simultaneous procedures
Case Report Page 1 of 5 Multiple joint reconstructions in one patient: computer-assisted simultaneous procedures Mahmoud Hafez, Hosamuddin Hamza, Raid Aumran Essa The Orthopaedic Department, October 6
More informationESCMID Online Lecture Library. by author
Therapies or diseases predisposing to infection Congenital immunodeficiences Acquired conditions Common variable immunedeficiency particular diseases (e.g. HIV, cancer,leukemia, lymphoma, diabetes, cystic
More informationInfections and Biologics
Overview Infections and Biologics James Galloway What is the risk of infection with biologics? Are some patients at greater risk? Are some drugs safer? Case scenario You recently commenced Judith, a 54
More informationRheumatology for the Internist 2017 Dr. Mark Matsos Associate Professor of Medicine Division of Rheumatology McMaster University
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON Rheumatology for the Internist 2017 Dr. Mark Matsos Associate Professor of Medicine Division of Rheumatology McMaster University CSIM
More informationMedical Policy Original Effective Date: Revised Date: 07/26/17 Page 1 of 9
Page 1 of 9 Disclaimer Description Coverage Determination/ Clinical Indications Refer to the member s specific benefit plan and Schedule of Benefits to determine coverage. This may not be a benefit on
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationBoth anatomic (atsa) and reverse (rtsa) total
S101 Comparison of Outcomes Using Anatomic and Reverse Total Shoulder Arthroplasty Pierre-Henri Flurin, M.D., Yann Marczuk, M.D., Martin Janout, M.D., Thomas W. Wright, M.D., Joseph Zuckerman, M.D., and
More informationBalgrist Shoulder Course 2017
Diagnosis and Management of Infection in Revision Shoulder Arthroplasty Joseph P. Iannotti MD, PhD Maynard Madden Professor and Chairman Orthopaedic and Rheumatologic Institute Cleveland Clinic Conflict
More informationNuclear medicine and Prosthetic Joint Infections
Nuclear medicine and Prosthetic Joint Infections Christophe Van de Wiele, M.D., Ph.D. Department of Nuclear Medicine, University Hospital Ghent, Belgium Orthopedic prostheses: world market 1996 Prosthetic
More informationSynoviocytes. Macrophage. B cell C H R O N I C. Neutrophil. Mast cell I N F L A M M A T I O N. Tissue cell. Endothelial cell. Th1/Th17 IL17 IL22
DC IL12, IL23 chemokines, ECM, Co-stimulation IL17, IL22 IFNγ ± Macrophage peptidoglycan lipopolysaccharide heat shock proteins Th1/Th17 IL17 IL22 Cell contact, co-stimulation immune complexes acute phase
More informationCost-Effective Solutions to Prevent Orthopedic Infections
Cost-Effective Solutions to Prevent Orthopedic Infections Am J Orthop. 2012 May;41(5):E76-E77 Authors: Hsu AR Author Affiliation Disclosures Andrew R. Hsu, MD Download pdf The unprecedented rising cost
More informationReport on New Patented Drugs - Orencia
Report on New Patented Drugs - Orencia Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board s Excessive
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationAdrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series
International Journal of Clinical Rheumatology For reprint orders, please contact: reprints@futuremedicine.com Adrenocorticotropic hormone gel in patients with refractory rheumatoid arthritis: a case series
More informationRole of irrigation and Debridement in PJI. S.M Kazemi associate professor, orthopedic surgeon SBM University Tehran Iran
Role of irrigation and Debridement in PJI S.M Kazemi associate professor, orthopedic surgeon SBM University Tehran Iran M Kazemi associate professor, orthopedic surgeon SBM University Tehran Iran Role
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationDIVISION OF QUALITY & PATIENT SAFETY. The National Comparative Effectiveness Summit, Washington D.C. 11/6/2012
Cost Effectiveness of MRSA Screening & Decolonization Joseph A. Bosco, MD, Vice Chair of Clinical Affairs James Slover, MD, MS, Associate Professor, Orthopaedic Surgeon Lorraine Hutzler, Quality Project
More informationTHE VALUE OF JOINT REPLACEMENT IN TREATING PATIENTS WITH OSTEOARTHRITIS
THE VALUE OF JOINT REPLACEMENT IN TREATING PATIENTS WITH OSTEOARTHRITIS Total Joint Replacement is a valuable treatment option for many of the 27 million Americans who suffer from Osteoarthritis, a disease
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 3 Report March 2012 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of the is to summarize
More informationAppendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months
Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview Study Name Year Reference ABATACEPT (n=7) Moreland 2002 Moreland LW, Alten R, Van den Bosch
More informationTofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients
doi: 10.2169/internalmedicine.9341-17 Intern Med Advance Publication http://internmed.jp ORIGINAL ARTICLE Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve
More informationComparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense
More informationContributions to health outcomes research Rheumatoid Arthritis. Study objective: Database: Author: Version: Date:
Contributions to health outcomes research Rheumatoid Arthritis Study objective: Database: Author: Version: Date: Analysis of patient journeys and their resource consumptions in Germany Insurants presenting
More informationP-1 (Former P-1) Are pediatric patients on oral or intravenous steroids at an increased risk of developing septic arthritis?
Pediatrics Prevention P-1 (Former P-1) Are pediatric patients on oral or intravenous steroids at an increased risk of developing septic arthritis? RESEARCHED BY: Muhammad Amin Chinoy MD, Pakistan Literature:
More informationCoffey et al ND 6 HA, 5 TSA, and 5 other MRSA (3) and Staphylococcus epidermidis (3)
Page 1 of 6 TABLE E-1 Outcomes of the Treatment of Periprosthetic Shoulder Infections* ä Study No. Presentation Prosthesis Most Common Pathogens Braman et al. 68 7 1 acute, 2 subacute, 2 HA and 5 TSA Staphylococcus
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationThe use of musculoskeletal ultrasound (MSKUS) as a. Musculoskeletal Ultrasound as a Diagnostic and Prognostic Tool in Rheumatoid Arthritis
215 Musculoskeletal Ultrasound as a Diagnostic and Prognostic Tool in Rheumatoid Arthritis Manish Jain, M.D., and Jonathan Samuels, M.D. Abstract The use of musculoskeletal ultrasound (MSKUS) has increased
More informationClinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid
Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis
More informationACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION
ACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0043I Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationJames R. O Dell, M.D. University of Nebraska Medical Center
Not everyone in the world needs a biologic: Lessons from TEAR and RACAT James R. O Dell, M.D. University of Nebraska Medical Center Disclosure Declaration James O Dell, MD Advisory Board for Crescendo,
More informationEtanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan
Adv Ther (2012) 29(8):691 697. DOI 10.1007/s12325-012-0039-3 ORIGINAL RESEARCH Etanercept and Adalimumab Treatment Patterns in Psoriatic Arthritis Patients Enrolled in a Commercial Health Plan Benjamin
More informationIncidence of DVT Post- Hip or Knee Replacement. A Comparison of Incidence at Boundary Trails Health Centre to a Credible Baseline Incidence
Incidence of DVT Post- Hip or Knee Replacement A Comparison of Incidence at Boundary Trails Health Centre to a Credible Baseline Incidence Background DVTs Pulmonary Embolisms Death Symptomatic DVTs (leg
More informationF-1 (Former F- 17) What are the important risk factors that predispose a patient to infection of total ankle arthroplasty?
Foot and Ankle Prevention F-1 (Former F- 17) What are the important risk factors that predispose a patient to infection of total ankle arthroplasty? RESEARCHED BY: Senneville, Eric MD, France Aiyer, Amiethab
More informationKEEP UP THE FIGHT WITH. Little Victories
FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) KEEP UP THE FIGHT WITH Little Victories Small improvements in your daily activities may be a sign that ORENCIA (abatacept) is working for you. Use this
More information